GeneDx Holdings Corp. (WGS) Stock Falls on Q1 2026 Earnings

GeneDx Holdings Corp. (WGS) reported first-quarter 2026 results.

Key income statement highlights:

Revenue of $102.3 million, up 17.38% year-over-year (consensus estimate: $114.1 million).

Gross profit of $68.2 million, up 16.65% year-over-year.

Cost of sales of $34.0 million, up 18.87% year-over-year.

Operating loss of -$57.5 million, a change of +1162.82% year-over-year.

Net loss attributable to common shareholders of -$63.3 million, a change of +869.77% year-over-year.

Profitability and per-share metrics:

Diluted loss per share was -2.16, versus an estimate of -0.0101.

Cash flow and balance sheet:

Cash used in operating activities: -$32.4 million (down 418.29% year-over-year).

Purchases of property, plant and equipment: -$6.5 million, up 5.29% year-over-year.

Cash and cash equivalents: $93.9 million, down 5.8% year-over-year.

Total liabilities: $252.2 million, up 33.41% year-over-year.

Market reaction:

Shares of WGS moved -32.95% since market close following the release.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

GeneDx Holdings Corp. Insider Trading Activity

GeneDx Holdings Corp. insiders have traded $WGS stock on the open market 91 times in the past 6 months. Of those trades, 10 have been purchases and 81 have been sales.

Here’s a breakdown of recent trading of $WGS stock by insiders over the last 6 months:

KEITH A. MEISTER has made 10 purchases buying 169,521 shares for an estimated $13,460,089 and 0 sales.
KATHERINE STUELAND (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 26 sales selling 107,892 shares for an estimated $8,724,277.
JOSHUA RUCH has made 0 purchases and 15 sales selling 38,000 shares for an estimated $6,093,967.
KEVIN FEELEY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 28 sales selling 27,205 shares for an estimated $2,376,762.
BRYAN DECHAIRO (Chief Operating Officer) has made 0 purchases and 12 sales selling 9,374 shares for an estimated $850,555.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive WGS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

GeneDx Holdings Corp. Hedge Fund Activity

We have seen 132 institutional investors add shares of GeneDx Holdings Corp. stock to their portfolio, and 157 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 581,515 shares (-81.0%) from their portfolio in Q4 2025, for an estimated $75,631,840
WESTFIELD CAPITAL MANAGEMENT CO LP added 474,167 shares (+87.1%) to their portfolio in Q4 2025, for an estimated $61,670,160
FRANKLIN RESOURCES INC added 411,607 shares (+60.4%) to their portfolio in Q4 2025, for an estimated $53,533,606
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC removed 410,928 shares (-33.7%) from their portfolio in Q4 2025, for an estimated $53,445,295
PENTWATER CAPITAL MANAGEMENT LP removed 375,000 shares (-88.2%) from their portfolio in Q4 2025, for an estimated $48,772,500
FMR LLC added 329,429 shares (+65.5%) to their portfolio in Q4 2025, for an estimated $42,845,535
JENNISON ASSOCIATES LLC removed 296,277 shares (-49.5%) from their portfolio in Q4 2025, for an estimated $38,533,786

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

GeneDx Holdings Corp. Analyst Ratings

Wall Street analysts have issued reports on $WGS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Canaccord Genuity issued a "Buy" rating on 12/22/2025

To track analyst ratings and price targets for GeneDx Holdings Corp., check out Quiver Quantitative's $WGS forecast page.

GeneDx Holdings Corp. Price Targets

Multiple analysts have issued price targets for $WGS recently. We have seen 5 analysts offer price targets for $WGS in the last 6 months, with a median target of $130.0.

Here are some recent targets:

Kyle Mikson from Canaccord Genuity set a target price of $100.0 on 04/20/2026
Subbu Nambi from Guggenheim set a target price of $100.0 on 03/30/2026
Mark Massaro from BTIG set a target price of $170.0 on 02/24/2026
David Westenberg from Piper Sandler set a target price of $130.0 on 02/24/2026
Brandon Couillard from Wells Fargo set a target price of $155.0 on 02/09/2026